John Overdeck Two Sigma Investments
John Overdeck is a co-founder of Two Sigma Investments, one of the world’s leading quantitative and technology-driven investment firms. Two Sigma applies data science, machine learning, and large-scale computing to markets across asset classes. Overdeck’s firm is a central reference point in discussions of modern systematic investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$510M |
| 2 |
Broadcom
AVGO
|
+$318M |
| 3 |
Marvell Technology
MRVL
|
+$290M |
| 4 |
Salesforce
CRM
|
+$263M |
| 5 |
Advanced Micro Devices
AMD
|
+$250M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$255M |
| 2 |
Progressive
PGR
|
+$244M |
| 3 |
Visa
V
|
+$238M |
| 4 |
Lam Research
LRCX
|
+$201M |
| 5 |
Elevance Health
ELV
|
+$190M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.88% |
| 2 | Healthcare | 13.28% |
| 3 | Financials | 10.32% |
| 4 | Industrials | 9.79% |
| 5 | Consumer Discretionary | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2951
Traeger
COOK
$156M
| $64.3K | ﹤0.01% |
765
-1,714
| -69% | -$190K |
|
2952
Arbutus Biopharma
ABUS
$1.03B
| $63.8K | ﹤0.01% |
18,286
-11,200
| -38% | -$37.4K |
|
2953
ADC Therapeutics
ADCT
$123M
| $63K | ﹤0.01% |
44,686
-138,545
| -76% | -$235K |
|
2954
Celularity
CELU
$22.4M
| $62.9K | ﹤0.01% |
36,380
-8,534
| -19% | -$16.2K |
|
2955
Flexible Solutions
FSI
$67.7M
| $62.7K | ﹤0.01% |
+12,424
| New | +$68.4K |
|
2956
Accuray
ARAY
$32.4M
| $62.7K | ﹤0.01% |
35,028
-37,453
| -52% | -$78.4K |
|
|
TPIC
2957
DELISTED
TPI Composites
TPIC
| $62.5K | ﹤0.01% |
+77,521
| New | +$101K |
|
2958
Sutro Biopharma
STRO
$340M
| $62.4K | ﹤0.01% |
9,588
-22,041
| -70% | -$347K |
|
2959
NRX Pharmaceuticals
NRXP
$149M
| $61.8K | ﹤0.01% |
+30,146
| New | +$84.9K |
|
2960
Veritone
VERI
$86M
| $61.1K | ﹤0.01% |
+26,260
| New | +$76.2K |
|
2961
Xilio Therapeutics
XLO
$60.5M
| $60.9K | ﹤0.01% |
6,005
+5,232
| +677% | +$65.8K |
|
|
BTLN
2962
Brightline Interactive
BTLN
$20.6M
| $57.4K | ﹤0.01% |
+49,461
| New | +$81.2K |
|
|
BIOA
2963
BioAge Labs
BIOA
$431M
| $56.9K | ﹤0.01% |
+15,145
| New | +$70K |
|
|
BGFV
2964
DELISTED
Big 5 Sporting Goods
BGFV
| $56.6K | ﹤0.01% |
58,569
-75,290
| -56% | -$103K |
|
2965
Werewolf Therapeutics
HOWL
$42.9M
| $56.5K | ﹤0.01% |
58,132
-35,308
| -38% | -$46.2K |
|
2966
Alto Neuroscience
ANRO
$1.42B
| $56.5K | ﹤0.01% |
26,142
-4,558
| -15% | -$16.3K |
|
|
BPT
2967
DELISTED
BP Prudhoe Bay Royalty Trust
BPT
| $55.6K | ﹤0.01% |
100,497
-502
| -0.5% | -$284 |
|
2968
Quince Therapeutics
QNCX
$34.1M
| $54.7K | ﹤0.01% |
206
+54
| +36% | +$16.5K |
|
2969
Getty Images
GETY
$107M
| $54.7K | ﹤0.01% |
+31,599
| New | +$75.2K |
|
2970
Immuneering
IMRX
$335M
| $54.4K | ﹤0.01% |
35,757
-14,800
| -29% | -$26.9K |
|
2971
iBio
IBIO
$70.5M
| $54.2K | ﹤0.01% |
+13,484
| New | +$52.4K |
|
2972
Richtech Robotics
RR
$362M
| $53.2K | ﹤0.01% |
26,886
-15,117
| -36% | -$37.2K |
|
|
SQNS
2973
Sequans Communications SA
SQNS
$45M
| $52.5K | ﹤0.01% |
2,499
-3,381
| -58% | -$92.3K |
|
2974
SELLAS Life Sciences
SLS
$2.89B
| $52.1K | ﹤0.01% |
+48,287
| New | +$57.3K |
|
|
BCG
2975
Binah Capital Group
BCG
$24.9M
| $51.9K | ﹤0.01% |
26,871
| – | – |
|
Similar funds
John Overdeck's Q1 2025 Portfolio in Review
As of Q1 2025, John Overdeck held 3,617 positions worth $46.8B, up 2% from $45.9B the previous quarter. Its ten largest holdings account for 8.1% of the portfolio.
John Overdeck deployed $2.08B of net new capital in Q1 2025, opening 458 new positions and adding to 1,225 existing holdings. Its largest new stake was Advanced Micro Devices: 2,246,952 shares worth $231M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Eli Lilly, an estimated $255M trimmed.
- John Overdeck's largest Q1 2025 buy was Advanced Micro Devices: 2,246,952 shares worth $231M.
- John Overdeck added most to State Street SPDR S&P 500 ETF Trust in Q1 2025, an estimated $510M increase.
- John Overdeck's biggest Q1 2025 reduction was Eli Lilly, cutting an estimated $255M.
- John Overdeck fully exited Coinbase in Q1 2025, selling an estimated $45M.
- John Overdeck's ten largest holdings make up 8.1% of its $46.8B portfolio in Q1 2025.
- John Overdeck opened 458 new positions and closed 452 in Q1 2025.
- John Overdeck's portfolio value rose 2% quarter-over-quarter to $46.8B.
Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.